GlassScriptPhysician profile
Anna Snowden
NPI 1912464322
$6,731.13
in general payments reported to CMS, 2019-2025
28 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $528 · 2022: $1,311 · 2023: $1,933 · 2024: $1,613 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,418 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,417.72 |
| Education | $474.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.08 | 2021-2025 | |
| Janssen Biotech, INC. | $763.85 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $553.96 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $488.35 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Amgen INC. | $470.82 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $461.34 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $446.50 | 2021-2025 | Bimzelx, Briviact |
| Pfizer INC. | $441.06 | 2021-2025 | |
| Merz North America, INC. | $440.34 | 2023-2024 | Xeomin |
| Genzyme Corporation | $254.30 | 2021-2025 | |
| Leo Pharma INC. | $228.88 | 2022-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $226.40 | 2021-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $185.50 | 2024 | |
| Dermavant Sciences, INC. | $157.35 | 2023-2024 | Vtama |
| Incyte Corporation | $154.11 | 2022-2025 | Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $129.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.32 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $83.14 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.39 | 2023-2024 | Spevigo |
| Mayne Pharma Commercial LLC | $43.13 | 2024 | |
| Galderma Laboratories, L.P. | $35.74 | 2024 | |
| Organon LLC | $31.60 | 2023-2025 | Hadlima, Vtama |
| Biofrontera INC. | $25.85 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Fresenius Kabi USA, LLC | $18.50 | 2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $17.39 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.01 | 2025 | Zoryve |
| Almirall LLC | $15.64 | 2022 | |
| Allergan, INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Snowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.